Table 3 Univariate analysis of variables... | American Society of Hematology

Table 3

Univariate analysis of variables potentially associated with neutrophil engraftment in 128 myeloablative double-unit CBT recipients

Variable	Category	HR (95%CI)	P
Recipient age (per decade)		0.90 (0.82-0.99)	.03
Disease type	Myeloid	Reference	.15
Disease type	Lymphoid	1.31 (0.91-1.88)	.15
Recipient CMV serology	Negative	Reference	.18
Recipient CMV serology	Positive	1.27 (0.89-1.82)	.18
Conditioning regimen	High-dose myeloablative	Reference	.49
Conditioning regimen	Reduced intensity*	1.13 (0.80-1.62)	.49
HLA allele match to recipient†	8-9/10	Reference	.98
	6-7/10	1.05 (0.66-1.67)
	2-5/10	1.02 (0.63-1.64)
Reported by bank prefreeze†	TNC dose × 10⁷/kg	1.19 (1.10-1.28)	<.001
Reported by bank prefreeze†	CD34+ cell dose × 10⁵/kg	1.39 (1.24-1.54)	<.001
Postthaw (infused) at MSKCC†	TNC dose × 10⁷/kg	1.28 (1.16-1.41)	<.001
	Viable CD34⁺ cell dose × 10⁵/kg	1.88 (1.58-2.24)	<.001
	CFU × 10⁴/kg	1.08 (1.03-1.13)	.001
	Viable CD3⁺ cell dose × 10⁶/kg	1.09 (1.02-1.16)	.006

Variable	Category	HR (95%CI)	P
Recipient age (per decade)		0.90 (0.82-0.99)	.03
Disease type	Myeloid	Reference	.15
Disease type	Lymphoid	1.31 (0.91-1.88)	.15
Recipient CMV serology	Negative	Reference	.18
Recipient CMV serology	Positive	1.27 (0.89-1.82)	.18
Conditioning regimen	High-dose myeloablative	Reference	.49
Conditioning regimen	Reduced intensity*	1.13 (0.80-1.62)	.49
HLA allele match to recipient†	8-9/10	Reference	.98
	6-7/10	1.05 (0.66-1.67)
	2-5/10	1.02 (0.63-1.64)
Reported by bank prefreeze†	TNC dose × 10⁷/kg	1.19 (1.10-1.28)	<.001
Reported by bank prefreeze†	CD34+ cell dose × 10⁵/kg	1.39 (1.24-1.54)	<.001
Postthaw (infused) at MSKCC†	TNC dose × 10⁷/kg	1.28 (1.16-1.41)	<.001
	Viable CD34⁺ cell dose × 10⁵/kg	1.88 (1.58-2.24)	<.001
	CFU × 10⁴/kg	1.08 (1.03-1.13)	.001
	Viable CD3⁺ cell dose × 10⁶/kg	1.09 (1.02-1.16)	.006

Conditioning was functionally myeloablative.

Dominant unit.